Temporal effects of low-dose ACE inhibition on endothelial function in Type 1 diabetic patients

Journal of Endocrinological Investigation

Volumn 30, Issue 9, 2007, Pages 726-733

  Yazici D ^a,c   Gogas Yavuz, D ^a   Unsalan S ^a   Toprak, A ^a   Yuksel M ^b   Deyneli, O ^a   Aydin H ^a   Tezcan, H ^a   Rollas, S ^a   Akalin, S ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

ACE inhibition; Asymmetrical dimethylarginine; Endothelial dysfunction; Oxidative stress; Type 1 diabetes mellitus

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANDOLAPRIL;

ADULT; AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MALE; VASODILATATION;

EID: 36949004766     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350809     Document Type: Article

References (41)

1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91: 2488-96.
2. Myrup B, Mathiesen ER, Ronn B, Deckert T. Endothelial function and serum lipids in the course of developing microalbuminuria in insulin-dependent diabetes mellitus. Diabetes Res 1994, 26: 33-9.
3. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993, 88: 2510-6.
4. Mullen MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. J Am Coll Cardiol 1998, 31: 1330-5.
5. Jorgensen RG, Russo L, Mattioli L, Moore WV. Early detection of vascular dysfunction in type I diabetes. Diabetes 1988, 37: 292-6.
6. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992, 90: 2548-54.
7. Elliott TG, Cockcroft JR, Groop PH, Viberti GC, Ritter JM. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 1993, 85: 687-93.
8. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and independent vasodilation studied at normoglycemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001, 44: 593-601.
9. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003, 166: 279-84.
10. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987, 59: 750-5.
11. Mittermayer F, Pleiner J, Krzyzanowska K, Wiesinger GF, Francesconi M, Wolzt M. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr 2005, 117: 816-20.
12. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 2002, 66: 811-5.
13. Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000, 20: 2039-44.
14. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimetyhlarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88: 1201-3.
15. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Inves 1997, 100: 678-84.
16. Arcaro G, Zenere BM, Saggiani F, et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care 1999, 22: 1536-42.
17. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999, 33: 1506-11.
18. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002, 90: 974-82.
19. Corretti MC, Anderson, TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39: 257-65.
20. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine and symmmetric dimethylarginine in human plasma and other biological samples by high performance liquid chromatography. Anal Biochem 2002, 303: 131-7.
21. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003, 22: 17-22.
22. Haklar G, Er sahin C, Moini H, et al. Involvement of free radicals in the cardioprotective effect of defibrotide. Arzneimittelforschung 1996, 46: 381-4.
23. Yagi K. Assay for blood plasma or serum. Methods Enzymol 1984, 105: 328-31.
24. Grisham MB, Johnson GG, Lancaster JR Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol 1996, 268: 237-46.
25. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999, 34: 631-8.
26. Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 2003, 145: 943-51.
27. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low-density lipoprotein cholesterol levels. J Am Coll Cardiol 1996, 28: 573-9.
28. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998, 98: 1842-7.
29. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99: 1141-6.
30. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976, 154: 179-84.
31. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo) 1995, 117: 237-8.
32. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994, 112: 43-8.
33. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 74: 1141-8.
34. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996, 97: 1916-23.
35. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99: 3092-5.
36. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Renin angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001, 65: 775-8.
37. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997, 96: 442-7.
38. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2: 3-9.
39. Kleber FX, Sabin GV, Winter UJ, et al. Angiotensin-converting enzyme inhibitors in preventing remodeling and development of heart failure after acute myocardial infarction: results of the German multicenter study of the effects of captopril on cardiopulmonary exercise parameters (ECCE). Am J Cardiol 1997, 80: 162A-7A.
40. Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000, 23: 234-40.
41. Farkas K, Jermendy G, Herold M, Ruzicska E, Sasvari M, Somogyi A. Impairment of the NO/cGMP pathway in the fasting and postprandial state in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2004, 112: 258-63.